These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 19243708

  • 1. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.
    Jain R, Osei K, Kupfer S, Perez AT, Zhang J.
    Pharmacotherapy; 2006 Oct; 26(10):1388-95. PubMed ID: 16999648
    [Abstract] [Full Text] [Related]

  • 3. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT.
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [Abstract] [Full Text] [Related]

  • 4. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of combined therapy for type 2 diabetes.
    Rodríguez A, Ciprés L, Tofé S, Polavieja P, Reviriego J.
    Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
    [Abstract] [Full Text] [Related]

  • 6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 7. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.
    Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
    [Abstract] [Full Text] [Related]

  • 8. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [Abstract] [Full Text] [Related]

  • 9. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [Abstract] [Full Text] [Related]

  • 10. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R, Xu Y, Abbadessa M, Quartet Study Group.
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [Abstract] [Full Text] [Related]

  • 11. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 12. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [Abstract] [Full Text] [Related]

  • 13. Thiazolidinediones and fractures in men and women.
    Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM.
    Arch Intern Med; 2009 Aug 10; 169(15):1395-402. PubMed ID: 19667303
    [Abstract] [Full Text] [Related]

  • 14. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 10; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 15. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr 10; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 16. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM, Le L, Zhang S, Harada AS.
    Pharmacoepidemiol Drug Saf; 2009 Feb 10; 18(2):166-74. PubMed ID: 19109802
    [Abstract] [Full Text] [Related]

  • 17. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P, Eiam-Ong S, Suwanwalaikorn S.
    J Med Assoc Thai; 2006 Feb 10; 89(2):170-7. PubMed ID: 16579002
    [Abstract] [Full Text] [Related]

  • 18. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
    Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B.
    Clin Endocrinol (Oxf); 2006 Jul 10; 65(1):35-9. PubMed ID: 16817816
    [Abstract] [Full Text] [Related]

  • 19. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr 10; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 20. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR.
    Cardiol Rev; 2009 Apr 10; 17(3):132-5. PubMed ID: 19384087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.